Novartis agrees to acquire Avidity Biosciences, an innovator in RNA therapeutics, strengthening its late-stage neuroscience ...
Ivo Carre, PhD, shares subgroup data that points to potential benefit in younger patients with high-risk MDS.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback